Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed360%
terminated120%
withdrawn120%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_2

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

NCT00327626
terminatedphase_2

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

NCT00330200
completedphase_2

Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

NCT00455598
completedphase_2

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

NCT00330330
completedphase_1

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

NCT00365781

Clinical Trials (5)

Showing 5 of 5 trials
NCT00327626Phase 2

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Withdrawn
NCT00330200Phase 2

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

Terminated
NCT00455598Phase 2

Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Completed
NCT00330330Phase 2

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Completed
NCT00365781Phase 1

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5